Hyperlipidaemia, hypertension
Conditions
Interventions
one group::Rosuvastatin 10mg for two days and Telmisartan 40mg for 14 days
Sponsors
Chinese University of Hong Kong
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Body mass index: 18-30 kg/m2; treatment with rosuvastatin 10 mg daily with or without other lipid-modifying drugs for at least for 4 weeks according to the current HA guidelines; borderline high or high blood pressure (systolic blood pressure >=120 mmHg or diastolic blood pressure >=80 mmHg) with or without anti-hypertensive treatment other than angiotensin-converting enzyme inhibitors (ACEIs) or ARBs.
Exclusion criteria
Exclusion criteria: History of hepatic, renal, biliary, cardiovascular, gastrointestinal, haematological and other chronic and acute diseases within 3 months prior to the study; clinically significant abnormality in physical examination, ECG evaluation, urine test, blood chemistry or haematological test or upon Investigator decision; adjustment of lipid-lowering treatment within 6 weeks prior to the study in patients with hyperlipidaemia; treatment of telmisartan or other ARBs or ACEIs within 4 weeks prior to the study; adjustment of concomitant medications within 4 weeks prior to the study; taking other drugs known to interact with rosuvastatin or telmisartan; volunteer in any clinical drug study within 2 months prior to this study; history of allergy or hypersensitivity to rosuvastatin or telmisartan; type 2 diabetes with poor glyceamic control (HbA1c> 8.5%); impaired hepatic or renal disease function (alanine aminotransferase [ALT] >1.5 times upper limit of normal range; serum creatinine > 140 mol/L); regular heavy alcohol consumption (>21 units of alcohol per week).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences in statin pharmacokinetic parameters with and without telmisartan; | — |
Secondary
| Measure | Time frame |
|---|---|
| Difference in pharmacokinetic parameters and interactions among genotype groups; | — |
Contacts
Public ContactBrian Tomlinson
Outcome results
None listed